Trials / Unknown
UnknownNCT03542422
Apatinib as First -Line Treatment for Advanced Esophagus Cancer
An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Affiliated Hospital of North Sichuan Medical College · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An Exploratory study of Amapinib for patients with advanced esophagus cancer .
Detailed description
An Exploratory study of Amapinib for patients with advanced esophagus cancer . Eligible are patients with advanced esophagus cancer. Apatinib (500mg) is given daily as follows: Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy One therapy cycle has 28 days. Tumor response is evaluated every 2 cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy. |
Timeline
- Start date
- 2018-06-30
- Primary completion
- 2018-12-01
- Completion
- 2019-05-01
- First posted
- 2018-05-31
- Last updated
- 2018-06-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03542422. Inclusion in this directory is not an endorsement.